Targeting glutamine metabolism by inhibiting the glutaminase isoenzyme with CB-839 or with a novel inhibitor of glutamine transporter, V-9302, in tumors addicted to glutamine is showing promise in cancer treatment, but it is insufficient as a monotherapeutic agent21. The gene discussed is GLS; the disease is cancer.